In man, the production of testosterone by the testes decreases slowly and progressively within the physiological aging process (approximately 1% year after 50 years)
Testosterone contributes to the general physical well-being of the adult man; in fact, it has been ascertained that physiological testosterone levels ensure optimal cholesterol values, inducing a decrease in total cholesterol and in “bad” cholesterol (LDL). The reduction of circulating testosterone levels in the male is instead responsible for the increased risk of Coronary Artery Disease, Obesity and Insulin Resistance, while normal testosterone concentrations can produce beneficial effects on the cardiovascular system. Testosterone also acts synergistically in increasing boldabol 200 en venta the effectiveness of active drugs on erection, which explains why low testosterone levels can attenuate the therapeutic response to currently available drugs.
This process is commonly referred to by the name of Andropause, Male Climaterio or, more appropriately, of ADAM, PADAM, (respectively English acronyms of Androgenic Decline in the Aging Male and Partial Androgenic Deficiency of The Aging Male) or LOH (Late-Onset Hypogonadism) – Late Hypogonadism).
ISSAM defines late hypogonadism as: A humoral syndrome associated with aging and characterized by a reduction in plasma androgen levels with or without a decrease in tissue sensitivity to androgens; as such it can lead to a significant alteration of the quality of life and compromise the functionality of numerous devices “.
Diagnosis of late hypogonadism
Dosage of testosterone in the blood
ADAM questionnaire
Late hypogonadism therapy
Exogenous administration of androgens. It proposes multiple objectives:
the restoration of normal desire and efficient sexual function;
the recovery of a normal condition of psycho-physical well-being;
the restoration of adequate bone mineral density;
The forms in which the androgenic hormones are currently available are different and include preparations for oral use, for short and long-acting intramuscular use, transdermal preparations.
In all subjects candidates for hormone replacement therapy with testosterone, particular attention must be paid to the exclusion of the presence of prostate cancer, the only true contraindication to this therapy; testosterone, while not inducing the appearance of prostate cancer, can facilitate the development of an already present tumor.
